- Antibodies against antibodies: immunogenicity of adalimumab as a model
- Award date
- 16 November 2012
- Number of pages
- Document type
- PhD thesis
- Faculty of Medicine (AMC-UvA)
- Upon repeated adalimumab exposure part of the patients start to produce ADA. The antibody response is polyclonal and consists mainly of antibodies of IgG1 and IgG4 isotype. In the majority of ADA positive patients ADA are already produced within the first 28 weeks of treatment and in part of the patients antibody production is transient. All antibodies are directed against the idiotype of adalimumab and result in functional neutralization of the drug.
- Research conducted at: Universiteit van Amsterdam
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.